United Kingdom Primary Hyperoxaluria (PH) Therapeutics Market Growing Trade Among Emerging Economies Opening New Opportunities (2023-2028)

Report Overview

The UK Primary Hyperoxaluria Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Primary Hyperoxaluria (PH) is an ultra-orphan disease caused by genetic mutations, which results in the build-up of overproduction and accumulation of oxalate in the body. This results in the deposition of calcium oxalate crystals in the kidneys and urinary tract, resulting in urolithiasis, nephrocalcinosis, and ultimately kidney failure. As a result of systemic oxalosis, multi-organ damage occurs which affects bones, eyes, skin, and the heart.

Affected individuals lack functional levels of a specific enzyme that normally prevents the accumulation of oxalate. In the kidneys, excess oxalate binds with calcium to form a hard compound (calcium oxalate) that is the main component of kidney and urinary stones. Common symptoms include the formation of stones throughout the urinary tract (urolithiasis) and kidneys (nephrolithiasis) and progressively increased levels of calcium in the kidneys (nephrocalcinosis).

There are three main types of PH that are inherited in an autosomal recessive pattern: PH1, PH2, and PH3. PH1 is the most severe primary hyperoxaluria and accounts for approximately 80% of cases. According to a study, primary hyperoxaluria has an estimated prevalence of 1 to 3 cases per 1 million population and an incidence rate of approximately 120,000 live births per year. It accounts for 1-2% of pediatric end-stage kidney disease but higher values are reported in specific populations with a high rate of consanguinity. The UK-based National Renal Rare Disease Registry (RaDaR) suggests there are approximately more than 100 patients across all the hospitals who have hyperoxaluria.

Market Growth Drivers

The increasing prevalence of primary hyperoxaluria disease is one of the major market drivers. However, with rising awareness and increased diagnostic facilities, demand for primary hyperoxaluria drugs is expected to be triggered over the forecast period. High investment in research & development by leading industry participants is expected to open a new growth window for them. With strong research and development initiatives, most of the companies are focusing on innovative and cost-effective drug development

An increase in special designation from the regulatory authority is propelling the growth of the PH market. Huge financial support to the researchers for developing novel interventions is boosting the market growth. The high demand for disease-specific novel treatment can also act as a market driver. The competitive scenario of the market and strategic collaborations may also boost the market position during the forecast period

Market Restraints

The high cost of treatment for primary hyperoxaluria acts as a major restraint for the market growth. Additionally, limited operating revenue opportunities for research and development of targeted therapies by many market players will be considered as a challenging factor for the growth of the PH market.

Get Exclusive Free Sample Report @ https://www.prudentmarkets.com/sample-request/139933/

Top Major Players

The UK's primary hyperoxaluria therapeutics market is a highly competitive market and major key players are adopting strategies; organic as well as inorganic market strategies. Alnylam Pharmaceuticals' Oxlumo is a synthetic double-stranded siRNA oligonucleotide; indicated for the treatment of primary hyperoxaluria in all age groups, the novel therapeutic possessing an orphan market exclusivity expiry till Nov 2030, expected to fosters the market growth. The prominent key players prevailing in the UK market are Alnylam Pharmaceuticals, Allena Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Intellia Therapeutics Inc, and OxThera AB among others.

The report delivers the challenges in front of the United Kingdom Primary Hyperoxaluria (PH) Therapeutics Market 2023 that allows a better understanding of the market providing a helpful comprehensive evaluation and clear-cut dynamics associated with this market. The analyst has studied the current market scenario while concentrating on the new business objectives with the lucrative opportunities that are available. This report includes changes in customer requirements, customer preferences, and the vendor landscape in the industry with key factors that are expected to influence the overall dynamics of the United Kingdom Primary Hyperoxaluria (PH) Therapeuticss Market including the current trends, growth opportunities, restraints, and market drivers.

To Know More About COVID-19 Impact On United Kingdom Primary Hyperoxaluria (PH) Therapeutics Market @ https://www.prudentmarkets.com/sample-request/139933/

Market Segmentation

By Diagnosis:

On the basis of diagnosis, the primary hyperoxaluria therapeutics market can be classified into

Blood Tests
Urine Tests
X-ray Examination
CT scanning
MRI Technique
Biopsy
Molecular genetic testing
Others

Investigation for PH includes measuring urine and plasma oxalate levels, ruling out the major causes of high oxalate levels. X-ray examinations can reveal the presence of kidney stones or calcium oxalate deposits in tissue. Computed tomography (CT) scanning, a specialized imaging technique, uses a computer and x-rays to create a film showing cross-sectional images of certain tissue structures such as kidney tissue. MRI can detect the severity of systemic oxalosis by imaging the retina, heart, and bone in greater detail. A biopsy involves the surgical removal and microscopic examination of a piece of affected tissue can also reveal the abnormal accumulation of oxalate. Molecular genetic testing for mutations in the specific genes known to cause PH confirms the diagnosis of PH.

By Drugs:

Based on the drugs, the primary hyperoxaluria therapeutics market can be bifurcated into

Oxlumo (lumasiran)
Calcium Oxalate Urinary Inhibitors
Thiazides
Pyridoxine

Oxlumo is a synthetic double-stranded siRNA oligonucleotide; indicated for the treatment of primary hyperoxaluria in all age groups, has been anticipated to attain a higher market share over the forecast period. Calcium Oxalate Urinary Inhibitors, like magnesium and orthophosphates, are most commonly preferred. Additionally, Thiazides used to decrease calcium in the urine and pyridoxine (vitamin B6) is known to reduce the body's production of oxalate, have been advocated to prevent kidney stones.

By Treatment:

Based on the treatment, the primary hyperoxaluria therapeutics market can be categorized into

shock wave lithotripsy
percutaneous nephrolithotomy
ureteroscopy
combined liver-kidney transplantation
sequential liver-kidney transplantation
isolated kidney transplant
isolated liver transplant

Treatment for kidney stones may involve shock wave lithotripsy, percutaneous nephrolithotomy, and ureteroscopy. Combined liver-kidney transplantation is an option whether pre-emptive or after the development of end-stage kidney damage. Depending on the response to other treatments and the disease severity, options may include a combined liver-kidney transplant; a sequential liver-kidney transplant; an isolated kidney transplant, or an isolated liver transplant. Transplantation requires life-long immune suppression and carries significant mortality risk.

By Distribution Channels:

In terms of distribution channel, the primary hyperoxaluria therapeutics market can be classified into

Hospital pharmacies
Retail pharmacies
Online pharmacies

In terms of value, the hospital pharmacies accounted for the leading market share in 2020, which is attributable to the fact that the majority of the medications for primary hyperoxaluria treatment are dispensed following by the prescription there and can so only be done by trained medical professionals. Hence, the hospital pharmacies segment is anticipated to enhance the market share over the forecast period.

Top Major Players

The UK's primary hyperoxaluria therapeutics market is a highly competitive market and major key players are adopting strategies; organic as well as inorganic market strategies. Alnylam Pharmaceuticals' Oxlumo is a synthetic double-stranded siRNA oligonucleotide; indicated for the treatment of primary hyperoxaluria in all age groups, the novel therapeutic possessing an orphan market exclusivity expiry till Nov 2030, expected to fosters the market growth. The prominent key players prevailing in the UK market are Alnylam Pharmaceuticals, Allena Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Intellia Therapeutics Inc, and OxThera AB among others.

The United Kingdom Primary Hyperoxaluria (PH) Therapeutics Market report is an easy-to-understand document giving section-wise details about the global market. Starting with the brief outline of the overall market, it will put forth the all-inclusive evaluated market statistics and different parameters for the forecast period. The report covers numerous aspects of the United Kingdom Primary Hyperoxaluria (PH) Therapeutics market divided into product kind, application, and end-use, offering the report to assist the customers in improving their ability to make precise decisions related to the business under the United Kingdom Primary Hyperoxaluria (PH) Therapeutics Market.

International Market Players will use the correct market facts and figures and applied math studies provided within the report back to perceive this and future growth of the worldwide Electrophoretic United Kingdom Primary Hyperoxaluria (PH) Therapeutics market. Each section of the research study is specially prepared to explore key aspects of the global United Kingdom Primary Hyperoxaluria (PH) Therapeutics Market. Buyers of the report will have access to accurate PESTLE, SWOT, and other types of analysis on the global United Kingdom Primary Hyperoxaluria (PH) Therapeutics market. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries.

This post-pandemic business planning research will aid clients to:
• Adjust their strategic planning to move ahead once business stability kicks in.
• Build resilience by making effective resource and investment choices for individual business units, products, and service lines.
• Conceptualize scenario-based planning to mitigate future crisis situations.

Instant Buy This Report and Get Up To 40% Discount [Use Corporate Email ID]: https://www.prudentmarkets.com/discount-request/139933/

Get full copy of 225+ pages research report (Inclusion of updated research on COVID-19) on United States Region at $1500 and, Europe region at $2000. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Our qualified team of researchers, analysts, and consultants use in-depth qualitative research, quantitative research, and the latest recognized research techniques to offer an unrivaled level of detail and value to your research activities. Our market and competitive intelligence can be utilized by teams across multiple departments, including sales and business development, marketing, to:

• Access the latest information on potential competitors and customers through a comprehensive database
• Analyse the business strategies and collaborations of multiple companies within a specific market
• Identify new markets and regions for future expansion
• Compare financial trends between competitor companies
• Get to know about mergers and acquisitions
• Explore the strengths and weaknesses of companies cross-industry
• Improve your business modeling

Strategic Points Covered in Table of Content of Global United Kingdom Primary Hyperoxaluria (PH) Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the United Kingdom Primary Hyperoxaluria (PH) Therapeutics market
Chapter 2: Exclusive Summary - the basic information of the United Kingdom Primary Hyperoxaluria (PH) Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the United Kingdom Primary Hyperoxaluria (PH) Therapeutics
Chapter 4: Presenting the United Kingdom Primary Hyperoxaluria (PH) Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the United Kingdom Primary Hyperoxaluria (PH) Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

(If you have any special requirements, please let us know and we will offer you the report as you want.)

Inquire Before Purchasing The Complete Report To Grow Your Business: https://www.prudentmarkets.com/enquiry-request/139933/

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.